Zydus has taken a significant step in advancing cancer treatment accessibility in India by introducing Olaparib, a PARP inhibitor, branded as IBYRA. This drug targets specific genetic mutations found in breast, ovarian, prostate, and pancreatic cancers, offering a more tailored and effective treatment approach. Among the 14 lakh newly diagnosed cancer patients in India, approximately 2.75 lakh are diagnosed with these specific cancers. Patients with HRD positivity or BRCA mutations are particularly suited for treatment with this PARP inhibitor, which can delay disease progression.
To assist in identifying suitable patients and ensuring access, Zydus has partnered with MedGenome for comprehensive HRD testing. Additionally, the year-long treatment with IBYRA has been priced at Rs. 3 lakhs, significantly lower than the innovator’s cost of around Rs. 72 lakhs.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the importance of early diagnosis and treatment for patients with these specific cancers. He highlighted Zydus’ commitment to patient support by offering cutting-edge diagnosis for HRD-positive cancer and precise therapy at an affordable cost, aiming to alleviate the disease burden for patients.
Zydus is a prominent player in the Indian oncology segment, known for launching several first-in-India biosimilars and therapies. With a patient-centric approach, the company has successfully provided access and affordability to cancer treatments. Six out of its eight oncology pillar brands, including Ujvira, Vivitra, Bryxta, Enfiera, Pegstim, and Obnyx, are leaders in their respective categories. This initiative underscores Zydus’ dedication to advancing cancer care and improving outcomes for patients across India.